Dianthus Therapeutics
DNTH
84.88
-0.52
-0.61%
Dianthus Therapeutics
US · DNTH
#2155 by market cap
Listed 1970
84.88
-0.52
-0.61%
Live - 5344 symbols - heartbeat 316s ago
· 2026-10-07 21:26
After-hours
84.88
0.00%
Overnight
85.24
+0.42%
- Market cap
- 4.75B
- P/E (TTM)i
- -20.02
- P/Bi
- 4.05
- EPSi
- -4.20
- Div yieldi
- 0.00%
- 52W posi
- 61%
Reader sentiment
Are you bullish or bearish on DNTH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 74.79, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 5 years
Latest year -67.35% YoY
Margins
- Operating margin
- -8,739.34%
- Net margin
- -7,973.33%
Key ratios & quality
- Altman Z-Scorei
- 74.79
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1.48M | 6.42M | 2.83M | 6.24M | 2.04M |
| Gross profit | -- | -- | -- | -- | -- |
| Selling & admin expenses | 1.96M | 6.74M | 18.16M | 24.99M | 34.33M |
| Research & development | 12.61M | 29.38M | 32.84M | 83.11M | 145.64M |
| Operating profit | -13.09M | -29.71M | -48.17M | -101.86M | -177.93M |
| Pretax profit | -13.11M | -28.48M | -43.56M | -84.97M | -162.34M |
| Tax | -- | -- | -- | -- | -- |
| Net profit | -13.11M | -28.48M | -43.56M | -84.97M | -162.34M |
| Basic EPS | -1 | -2 | -8 | -3 | -4 |
| Diluted EPS | -0.88 | -1.92 | -8.45 | -2.55 | -4.20 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.16M | 193.00K | 396.00K | 284.00K | 463.00K | 761.00K |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 7.34M | 8.87M | 8.20M | 9.93M | 12.47M | 13.56M |
| Research & development | 27.00M | 26.25M | 32.49M | 59.90M | 34.53M | 48.69M |
| Operating profit | -33.18M | -34.93M | -40.29M | -69.54M | -46.53M | -61.48M |
| Pretax profit | -29.51M | -31.63M | -36.77M | -64.43M | -40.83M | -50.22M |
| Tax | -- | -- | -- | -- | -- | -- |
| Net profit | -29.51M | -31.63M | -36.77M | -64.43M | -40.83M | -50.22M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.82 | -0.88 | -0.97 | -1.43 | -0.85 | -0.90 |
Balance sheet
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total current assets | 9.39M | 82.03M | 177.45M | 280.90M | 409.44M |
| Cash & ST investments | 7.64M | 75.49M | 173.72M | 275.24M | 404.30M |
| Inventory | -- | -- | -- | -- | -- |
| Total assets | 9.45M | 83.11M | 179.41M | 374.01M | 530.92M |
| Total current liabilities | 5.35M | 8.23M | 9.63M | 18.45M | 30.73M |
| Short-term debt | -- | 350.00K | 417.00K | 320.00K | 367.00K |
| Long-term debt | -- | -- | -- | -- | -- |
| Total liabilities | 26,700,000.00 | 9,454,000.00 | 10,535,000.00 | 21,531,000.00 | 37,521,000.00 |
| Total equity | -17.25M | 73.66M | 168.87M | 352.48M | 493.40M |
| Retained earnings | -17.39M | -45.87M | -89.42M | -174.39M | -336.73M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 271.00M | 263.61M | 413.83M | 409.44M | 1.12B | 897.54M |
| Cash & ST investments | 263.23M | 257.39M | 402.61M | 404.30M | 1.11B | 886.81M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 348.58M | 326.08M | 577.45M | 530.92M | 1.25B | 1.21B |
| Total current liabilities | 16.95M | 20.09M | 23.86M | 30.73M | 38.28M | 34.39M |
| Short-term debt | 226.00K | 211.00K | 217.00K | 367.00K | 399.00K | 374.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 19,974,000.00 | 22,997,000.00 | 30,991,000.00 | 37,521,000.00 | 45,570,000.00 | 41,246,000.00 |
| Total equity | 328.61M | 303.08M | 546.45M | 493.40M | 1.20B | 1.17B |
| Retained earnings | -203.90M | -235.53M | -272.30M | -336.73M | -377.56M | -427.78M |
Cash flow
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating cash flow | -9.90M | -29.07M | -36.86M | -78.18M | -129.06M |
| Depreciation & amortization | 0 | 147.00K | 355.00K | 412.00K | 428.00K |
| Free cash flow | -9.94M | -29.21M | -36.97M | -78.29M | -129.27M |
| Dividends paid | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 72.00M | 269.20M | 272.27M |
| Ending cash balance | 7.64M | 15.43M | 132.39M | 23.02M | 51.25M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -27.63M | -23.89M | -30.56M | -46.98M | -28.86M | -48.98M |
| Depreciation & amortization | 133.00K | 99.00K | 99.00K | 97.00K | 76.00K | 107.00K |
| Free cash flow | -27.65M | -23.94M | -30.56M | -47.12M | -28.87M | -49.16M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 272.27M | 0 | 736.36M | 0 |
| Ending cash balance | 10.35M | 13.47M | 56.15M | 51.25M | 627.84M | 110.72M |
Returns & efficiency
| Line item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| ROE %i | -- | -- | -69.97 | -32.60 | -38.38 |
| ROA %i | -138.70 | -61.53 | -33.18 | -30.71 | -35.88 |
| ROIC %i | -- | -- | -76.77 | -39.10 | -42.05 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- |
| EBIT margin %i | -886.59 | -462.91 | -1,704.67 | -1,633.75 | -8,739.34 |
| FCF / sales %i | -- | -- | -- | -- | -- |
| Current ratioi | 1.75 | 9.97 | 18.42 | 15.22 | 13.32 |
| Quick ratioi | 1.70 | 9.86 | 18.09 | 14.96 | 13.16 |
| Debt / assetsi | 0.00 | 0.95 | 0.33 | 0.40 | 0.26 |
| LT debt / equityi | -- | -- | 0.10 | 0.33 | 0.21 |
| Interest coveragei | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | 61.65 | -31.80 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -28.73 | -34.71 | -28.57 | -38.38 | -22.70 | -26.07 |
| ROA %i | -27.56 | -33.02 | -27.12 | -35.88 | -21.77 | -24.98 |
| ROIC %i | -33.47 | -39.33 | -31.87 | -42.05 | -25.09 | -29.64 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,796.40 | -2,676.56 | -4,558.41 | -8,739.34 | -14,318.04 | -11,441.39 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 15.99 | 13.12 | 17.35 | 13.32 | 29.25 | 26.10 |
| Quick ratioi | 15.59 | 12.81 | 17.09 | 13.16 | 29.06 | 25.79 |
| Debt / assetsi | 0.40 | 0.41 | 0.22 | 0.26 | 0.11 | 0.11 |
| LT debt / equityi | 0.36 | 0.37 | 0.20 | 0.21 | 0.08 | 0.08 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing next-generation therapies to transform the treatment of severe autoimmune diseases100.00%
Quote time 2026-10-07 21:26:06 · For reference only, not investment advice and not tailored to your situation.